10-Deacetyl-7-xylosyl paclitaxel
10-Deacetyl-7-xylosyl paclitaxel has long been used in Chinese clinics to treat cancer, it may target mitochondrial permeability transition pore (mPTP).
Inquire / Order:
manager@chemfaces.com
Technical Inquiries:
service@chemfaces.com
Tel:
+86-27-84237783
Fax:
+86-27-84254680
Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to
24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com
The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
mBio.2020, 11(3):e00686-20.
Pharmacological Reports2020, 1-9
Neurochem Int.2020, 133:104629
Nutrients.2019, 11(4):E936
Oncotarget.2017, 8(53):90925-90947
Phytomedicine.2022, 99:154025.
Anticancer Res.2014, 34(7):3505-9
J Ethnopharmacol.2017, 198:205-213
Functional Ecology2020, doi: 10.1111.
Crystals2020, 10(3), 206.
Related and Featured Products
Planta Med. 2010 Oct;76(14):1592-5.
Transport of a hydrophilic paclitaxel derivative, 7-xylosyl-10-deacetylpaclitaxel, by human intestinal epithelial Caco-2 cells.[Pubmed:
20414861 ]
7-Xylosyl-10-deacetylpaclitaxel(10-Deacetyl-7-xylosyl paclitaxel) is an active compound used in traditional Chinese medicine to treat cancer. However, pharmacokinetic studies yielded low plasma concentrations of 7-xylosyl-10-deacetylpaclitaxel after its oral administration in preclinical trials.
Therefore, we investigated whether the observed low oral bioavailability of this compound is due to poor absorption.
METHODS AND RESULTS:
We studied the transepithelial flux of 7-xylosyl-10-deacetylpaclitaxel using the human colonic cell line Caco-2 as a model and found out that its flux (at a concentration range of 0.5-20 μM) across the Caco-2 cell layer was linear with time for up to 3 hr. The apparent maximal concentration (K (M)) of the active efflux component was 93.4 μM. Verapamil (50 μM) and tetrandrine (25 μM) significantly decreased the active transport component.
CONCLUSIONS:
These data support the conclusion that rapid passive diffusion of 7-xylosyl-10-deacetylpaclitaxel through the intestinal epithelium is partially counteracted by the action of an outwardly directed efflux pump, presumably P-glycoprotein. The relatively high apparent permeability coefficient ( P(app)) for the apical to basolateral 7-xylosyl-10-deacetylpaclitaxel transport (16.3 ± 6.3 × 10 (-6) cm/s; n = 3) suggests that the drug may still be effectively absorbed in the intestinal tract.
